METHOD OF TREATING CANCER BY ADMINISTRATION OF AN ANTI-PD-1 OR ANTI-PD-L1 THERAPEUTIC AGENT VIA A LYMPHATIC MICRONEEDLE DELIVERY DEVICE
Methods, devices and systems for delivery of an anti-PD-1 or an anti-PD-L1 therapeutic agent to the lymphatic system for treating cancer in a patient are described.
1 . A method of treating cancer in a patient, comprising:
placing a device comprising a plurality of microneedles on the skin of the patient proximate to a first position under the skin of the patient, wherein the first position is proximate to lymph vessels and/or lymph capillaries in the patient's lymphatic system, and wherein the microneedles have a surface comprising nanotopography;
inserting the plurality of microneedles into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the first position; and
administering via the plurality of microneedles to the first position an effective amount of an anti-PD-1 therapeutic agent or an effective amount of an anti-PD-L1 therapeutic agent to treat cancer in a patient.
2 . A method of preventing or reducing cancer metastasis in a patient, comprising:
locating at least one lymph node in the patient that intervenes in the lymphatic system between a solid cancer tumor and a draining duct;
placing a device comprising a plurality of microneedles on the skin of the patient proximate to a first position under the skin of the patient located between the intervening lymph node and the solid cancer tumor, wherein the first position is proximate to lymph vessels and/or lymph capillaries in the patient's lymphatic system, and wherein the microneedles have a surface comprising nanotopography;
inserting the plurality of microneedles into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the first position; and
administering via the plurality of microneedles to the first position a therapeutically effective amount of an anti-PD-1 therapeutic agent or an anti-PD-L1 therapeutic agent that is effective for preventing or reducing cancer metastasis in the patient.
3 . A method of preventing or reducing cancer metastasis in a patient, comprising:
locating a solid cancer tumor in the patient;
locating at least one lymph node in the patient that intervenes in the lymphatic system between the solid cancer tumor and a draining duct;
placing a device that comprises a plurality of microneedles on the skin of the patient at a first location on the skin of the patient that is proximate to lymph capillaries and/or lymph vessels that flow into the intervening lymph node, wherein the microneedles have a surface comprising nanotopography;
inserting the plurality of microneedles into the patient to a depth whereby at least the epidermis is penetrated; and
administering via the plurality of microneedles to the lymph capillaries and/or lymph vessels that flow into the intervening lymph node a therapeutically effective amount of an anti-PD-1 therapeutic agent or an anti-PD-L1 therapeutic agent that is effective in preventing or reducing cancer metastasis in the patient.
4 . The method of claim 1 , wherein the cancer comprises a tumor.
5 . The method of claim 1 , wherein the lymph node is a tumor draining lymph node.
6 . The method of claim 1 , wherein the cancer is a cancer susceptible to treatment with an anti-PD-1 therapeutic agent or anti-PD-L1 therapeutic agent.
7 . The method of claim 1 , wherein serum bioavailability of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent is up to 10%, 15% 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70%.
8 . The method of claim 1 , wherein a serum Tmax of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent is from 10 to 100 hours.
9 . The method of claim 1 , wherein a serum Cmax of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent is decreased up to 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, or 4-fold, as compared to a serum Cmax following an equivalent amount of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent administered by an intravenous delivery route.
10 . The method of claim 1 , wherein a serum AUC 0-t of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent is decreased up to 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, or 4-fold as compared to a serum AUC 0-t following an equivalent amount of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent administered by an intravenous delivery route.
11 . The method of claim 1 , wherein delivery of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent to one or more lymph nodes is increased up to 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, or 4-fold as compared to delivery to one or more lymph nodes of an equivalent amount of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent administered by an intravenous delivery route.
12 . The method of claim 1 , wherein levels of the anti-PD-1 therapeutic agent or anti-PD-L1 therapeutic agent in one or more systemic organs is decreased 10-75% over a period of time as compared to levels in one or more systemic organs following an equivalent amount of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent administered by an intravenous delivery route over a same period of time.
13 . The method of claim 12 , wherein the organ is a liver or a kidney.
14 . The method of claim 12 , wherein the period of time is up to 12 hours, 24 hours, 36 hours, 48 hours, 60 hours, or 72 hours.
15 . The method of claim 1 , wherein the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent is at least 90%, 95%, 99%, or 99.9% cleared from the patient's serum by 28 days after administration.
16 . The method of claim 1 , wherein the administering results in an undetectable primary tumor and/or an undetectable secondary tumor.
17 . The method of claim 16 , wherein an incidence or probability of an undetectable primary tumor and/or an undetectable secondary tumor is at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99%.
18 . The method of claim 1 , wherein exposure of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent to T-cells in the patient's lymphatic system is increased up to 1.5-fold, 2-fold, or 2.5-fold, as compared to exposure to T-cells in the patient's lymphatic system following an equivalent amount of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent administered by an intravenous delivery route.
19 . The method of claim 1 , wherein exposure of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent to one or more solid cancer tumors in the patient's lymphatic system is increased up to 1.5-fold, 2-fold, or 2.5-fold, as compared to exposure to one or more solid cancer tumors in the patient's lymphatic system following an equivalent amount of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent administered by an intravenous delivery route.
20 . The method of claim 1 , wherein tumor-infiltrating lymphocytes are increased up to 1.5-fold, 2-fold, or 2.5-fold as compared to tumor-infiltrating lymphocytes following an equivalent amount of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent administered by an intravenous delivery route.
21 . The method of claim 1 , wherein incidence or severity of one or more immune-related Adverse Events is reduced as compared to one or more immune-related Adverse Events following an equivalent amount of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent administered by an intravenous delivery route.
22 . The method of claim 1 , wherein tumor growth inhibition is increased up to 10-fold, 20-fold, 30-fold, 40-fold, or 50-fold compared to tumor growth inhibition following an equivalent amount of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent administered by an intravenous delivery route.
23 . The method of claim 1 , wherein tumor growth inhibition is equal to or better than tumor growth inhibition following up to 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, or 5-fold greater amount of the anti-PD-1 therapeutic agent or the anti-PD-L1 therapeutic agent administered by an intravenous delivery route.